Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Trial details
- Registry ID
- NCT05126433
- Phase
- Phase 2
The FDA approved Lurbinectedin (Zepzelca) on 15 Jun 2020.
Drug identity checked against registry records
Also recorded as Zepzelca
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid TumorsNCT05126433 | Jazz Pharmaceuticals | Phase 2 | Terminated | 2023-12-20Actual |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCNCT07459634 | Jazz Pharmaceuticals | Phase 2 | Recruiting | 2029-08-04Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2020-06-15Day | Lurbinectedin | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA213702", "applicant_as_listed_by_fda": "JAZZ", "brand_names": ["ZEPZELCA"], "active_ingredients": ["LURBINECTEDIN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20200615", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |